Provided by Tiger Trade Technology Pte. Ltd.

Rhythm Pharmaceuticals Inc.

99.34
+2.572.66%
Volume:261.69K
Turnover:26.15M
Market Cap:6.84B
PE:-31.87
High:100.85
Open:97.69
Low:97.21
Close:96.77
52wk High:122.20
52wk Low:74.50
Shares:68.85M
Float Shares:65.39M
Volume Ratio:1.60
T/O Rate:0.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1172
EPS(LYR):-3.1100
ROE:-117.04%
ROA:-30.96%
PB:66.42
PE(LYR):-31.94

Loading ...

BRIEF-Rhythm Pharmaceuticals Q1 Net Income USD -55.639 Million Vs. IBES Estimate USD -55.3 Million

Reuters
·
May 05

Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

THOMSON REUTERS
·
May 05

Rhythm Pharmaceuticals presents Phase 3 TRANSCEND trial data

TIPRANKS
·
May 04

BRIEF-Rhythm Pharmaceuticals Announces New Data Presentations In Acquired Hypothalamic Obesity At Pediatric Endocrine Society

Reuters
·
May 04

Rhythm presents 2.5-year setmelanotide data in pediatric acquired hypothalamic obesity trial

Reuters
·
May 04

Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society

THOMSON REUTERS
·
May 04

BUZZ-U.S. STOCKS ON THE MOVE-Perella Weinberg Partners, Amkor Technology, Esperion Therapeutics

Reuters
·
May 02

BUZZ-U.S. STOCKS ON THE MOVE-Paramount Skydance, Newell Brands, Rhythm,

Reuters
·
May 01

BUZZ-Rhythm rises after European Commission approves drug for rare form of obesity

Reuters
·
May 01

EU grants Rhythm’s Imcivree approval for acquired hypothalamic obesity treatment

Reuters
·
May 01

Rhythm Pharmaceuticals Announces Imcivree® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients With Acquired Hypothalamic Obesity

THOMSON REUTERS
·
May 01

Rhythm Pharmaceuticals Inc - Commercial Launches of Imcivree in Europe Anticipated in 2027

THOMSON REUTERS
·
May 01

Earning Preview: Rhythm Pharmaceuticals Inc. this quarter’s revenue is expected to increase by 38.35%, and institutional views are bullish

Earnings Agent
·
Apr 28

Analysts Conflicted on These Healthcare Names: Rhythm Pharmaceuticals (RYTM) and Sarepta Therapeutics (SRPT)

TIPRANKS
·
Apr 17

Rhythm Pharmaceuticals updates financial calendar with first-quarter results call

Reuters
·
Apr 09

Why Rhythm Pharmaceuticals (RYTM) Is Up 12.6% After EU IMCIVREE Expansion Boost and Board Refresh – And What's Next

Simply Wall St.
·
Apr 08

Rhythm Pharmaceuticals appoints Popovits to board of directors

TIPRANKS
·
Apr 06

A Look At Rhythm Pharmaceuticals (RYTM) Valuation After IMCIVREE Approval Expands Obesity Treatment Reach

Simply Wall St.
·
Apr 04

Rhythm Pharmaceuticals appoints Kim Popovits to board as Ed Mathers exits

Reuters
·
Apr 03

Rhythm Pharmaceuticals Announces Changes to Board of Directors

THOMSON REUTERS
·
Apr 03